TP53 and non-small cell lung carcinoma: Previous studies had shown that compared with the corresponding wild-type tumors, TP53 mutant NSCLC expressed higher levels of PD-L1 protein, promoted T cell infiltration, and enhanced tumor immunogenicity [27, 28].